1/21
Looks like no tags are added yet.
Crohn’s disease (regional enteritis)
A chronic inflammatory disorder characterized by alternating periods of remission and exacerbation
Involves subacute or long-term inflammation of the GI tract that affects the full thickness of the bowel wall, known as a transmural lesion
Although it can affect any part of the GI tract, it most commonly involves the distal ileum and ascending colon
RLQ abdominal pain
Diarrhea
Crampy abdominal pain (especially after meals)
Abdominal tenderness and spasm
Decreased food intake (weight loss, malnutrition, secondary anemia)
Steatorrhea
Abdominal and anal abscesses, fistulas, anal fissures
Clinical manifestations of Crohn’s disease
Family history of IBD (first-degree relative)
Female sex
Age 20-29
Caucasian ethnicity
Ashkenazi Jewish background
Living in a northern climate and urban area
Current smoker
Exposure to environmental triggers (air pollutants)
Abnormal or excessive cell-mediated immune response
Etiology/risk factors of Crohn’s disease
Chronic diarrhea, RLQ abdominal pain, post-meal cramping, fatigue, and weight loss
Assess appetite, weight, malnutrition, dehydration, and electrolyte imbalance
Abdominal distention and perianal lesions or fistulas. Assess bowel sounds. Assess tympany and abnormal dullness. Check for RLQ tenderness, guarding, or masses
Strictures, obstruction, fistulas, abscesses, and perforation
Key assessments of Crohn’s disease
Assess abdominal pain, bowel movement, and sounds. Monitor vital signs, weight, intake and output, and signs of dehydration
Assess nutritional status and monitor laboratory values such as CBC, electrolytes, and albumin
Encourage small, frequent meals, and adequate fluid intake
Nursing management of Crohn’s disease
Nutritional support through a high-calorie, high-protein diet when tolerated
Vitamin and mineral supplementation, especially iron, vitamin B12, vitamin D, and calcium
Enteral nutrition or Total Parenteral Nutrition may be needed in severe cases
Medical management of Crohn’s disease
Aminosalicylates (5-ASA), such as Mesalamine and Sulfasalazine
[PHARMACOLOGICAL MANAGEMENT OF CROHN’S]
Used to reduce intestinal inflammation, particularly in mild disease
Corticosteroids (Prednisone and Budesonide)
[PHARMACOLOGICAL MANAGEMENT OF CROHN’S]
Prescribed during acute flare ups, but are not recommended for long-term maintenance because of adverse effects
Immunomodulators (Azathioprine, 6-Mercaptopurine, and Methotrexate)
[PHARMACOLOGICAL MANAGEMENT OF CROHN’S]
Helps suppress the immune response and maintain remission
Biologic agents (Infliximab, Adalimumab)
[PHARMACOLOGICAL MANAGEMENT OF CROHN’S]
Used for moderate to severe disease that does not respond to conventional therapy
Antibiotics (Metronidazole, Ciprofloxacin)
[PHARMACOLOGICAL MANAGEMENT OF CROHN’S]
May be prescribed when fistulas, abscesses, or bacterial infections are present
Diet
Foods to limit or avoid if triggering symptoms
Hydration
Medication
Symptom monitoring
When to seek help
Lifestyle
Health education for Crohn’s disease
Ulcerative colitis
A chronic inflammatory condition affecting the mucosal and submucosal layers of the colon and rectum
Characterized by unpredictable periods of remission and exacerbation, often accompanied by abdominal cramping and bloody or pus-containing diarrhea
The inflammation usually starts in the rectum and gradually extends upward through the colon
Diarrhea with mucus, pus, or blood
LLQ abdominal pain
Intermittent tenesmus
Rectal bleeding (anemia, fatigue, pallor)
Abdominal cramping
Clinical manifestations of ulcerative colitis
Family history of IBD (first-degree relative)
Male sex
Age 15-30 and > 60 years old
Caucasian ethnicity
Ashkenazi Jewish background
Living in a northern climate and urban area
Former smoker or non-smoker
Exposure to environmental triggers (air pollutants)
Abnormal or excessive cell-mediated immune response
Etiology/risk factors of ulcerative colitis
Bloody diarrhea with mucus, LLQ abdominal pain, urgency, tenesmus, and fatigue.
Assess for weight loss, anemia, dehydration, and electrolyte imbalance.
Assess for pallor and abdominal distention. Assess bowel sounds. Assess for tympany and abnormal distention. Check for LLQ tenderness, guarding, or rigidity.
Toxic megacolon, severe hemorrhage, and perforation.
Key assessments for ulcerative colitis
Monitor stool frequency, consistency, and the presence of blood or mucus. Assess abdominal pain, bowel sounds, and abdominal tenderness.
Monitor hydration status, intake and output, daily weight, and electrolyte levels. Encourage adequate fluid intake and provide a low-residue diet during flare-ups. Promote adequate rest to reduce fatigue
Administer prescribed medications and monitor for side effects. Educate the patient about medication adherence, dietary modifications, stress reduction, and recognizing signs of worsening disease.
Nursing management for ulcerative colitis
Provide nutritional support with adequate calories and protein. Correct fluid and electrolyte imbalances caused by diarrhea.
Blood transfusion may be necessary for severe bleeding and anemia.
Surgery may be recommended for severe disease, toxic megacolon, perforation, or colorectal cancer.
Medical management for ulcerative colitis
Aminosalicylates (5-ASA) (Mesalamine, Sulfasalazine)
[PHARMACOLOGICAL MANAGEMENT FOR ULCERATIVE COLITIS]
Are the first-line treatment for mild to moderate ulcerative colitis
Immunomodulators (Azathioprine, 6-Mercaptopurine)
[PHARMACOLOGICAL MANAGEMENT FOR ULCERATIVE COLITIS]
Are prescribed to maintain remission and reduce corticosteroid dependence
Biologic agents (Infliximab, Adalimumab, Vedolizumab, and Ustekinumab)
[PHARMACOLOGICAL MANAGEMENT FOR ULCERATIVE COLITIS]
Are indicated for moderate to severe ulcerative colitis that is unresponsive to conventional treatment
Diet
Foods to limit
Hydration
Medication adherence
Bowel monitoring
When to seek help
Colon health and follow-up
Health education for ulcerative colitis